157 related articles for article (PubMed ID: 2941177)
41. Time-related effects of a triphenylethylene antiestrogen on estrogen-induced changes in uterine weight, estrogen receptors, and endometrial sensitivity in rats.
Trivedi RN; Chauhan SC; Dwivedi A; Kamboj VP; Singh MM
Contraception; 1995 Jun; 51(6):367-79. PubMed ID: 7554978
[TBL] [Abstract][Full Text] [Related]
42. Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer.
Mäenpää J; Sipilä P; Kangas L; Karnani P; Grönroos M
Gynecol Oncol; 1992 Sep; 46(3):292-7. PubMed ID: 1388131
[TBL] [Abstract][Full Text] [Related]
43. Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions.
Laxmi YR; Liu X; Suzuki N; Kim SY; Okamoto K; Kim HJ; Zhang G; Chen JJ; Okamoto Y; Shibutani S
Int J Cancer; 2010 Oct; 127(7):1718-26. PubMed ID: 20073065
[TBL] [Abstract][Full Text] [Related]
44. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Gottardis MM; Jordan VC
Cancer Res; 1987 Aug; 47(15):4020-4. PubMed ID: 3607747
[TBL] [Abstract][Full Text] [Related]
45. Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice.
Koh J; Kubota T; Asanuma F; Yamada Y; Kawamura E; Hosoda Y; Hashimoto M; Yamamoto O; Sakai S; Maeda K
J Surg Oncol; 1992 Dec; 51(4):254-8. PubMed ID: 1434657
[TBL] [Abstract][Full Text] [Related]
46. The significance of estrogen receptors in tamoxifen and toremifene therapy.
Valavaara R; Kangas L
Ann Clin Res; 1988; 20(5):380-8. PubMed ID: 2975479
[TBL] [Abstract][Full Text] [Related]
47. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Chisamore MJ; Ahmed Y; Bentrem DJ; Jordan VC; Tonetti DA
Clin Cancer Res; 2001 Oct; 7(10):3156-65. PubMed ID: 11595710
[TBL] [Abstract][Full Text] [Related]
48. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.
Chander SK; McCague R; Luqmani Y; Newton C; Dowsett M; Jarman M; Coombes RC
Cancer Res; 1991 Nov; 51(21):5851-8. PubMed ID: 1933854
[TBL] [Abstract][Full Text] [Related]
49. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
[TBL] [Abstract][Full Text] [Related]
51. Antiestrogen therapy: uncertainties and risk assessment.
Smith LL; White IN
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):14-22. PubMed ID: 9556786
[TBL] [Abstract][Full Text] [Related]
52. Effects of the antiestrogen toremifene on growth of the human mammary carcinoma cell line MCF-7.
Grenman R; Laine KM; Klemi PJ; Grenman S; Hayashida DJ; Joensuu H
J Cancer Res Clin Oncol; 1991; 117(3):223-6. PubMed ID: 1827796
[TBL] [Abstract][Full Text] [Related]
53. Differences in morphology and cytoskeleton of MCF-7 and MX-1 cells after therapy with OH-tamoxifen and the pure estrogen antagonist ZM 182780. An immunofluorescence and scanning electron microscopic study.
Ehlers EM; Schubert C
Ann Anat; 1999 May; 181(3):231-6. PubMed ID: 10363104
[TBL] [Abstract][Full Text] [Related]
54. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor.
Zajchowski DA; Sager R; Webster L
Cancer Res; 1993 Oct; 53(20):5004-11. PubMed ID: 8402691
[TBL] [Abstract][Full Text] [Related]
55. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.
Clemens JA; Bennett DR; Black LJ; Jones CD
Life Sci; 1983 Jun; 32(25):2869-75. PubMed ID: 6406781
[TBL] [Abstract][Full Text] [Related]
56. A comparison of the efficacy for antitumor activity of the non-steroidal antiestrogens analog II and tamoxifen in 7,12-dimethylbenz[a] anthracene-induced rat mammary tumors.
Pento JT; Magarian RA; King MM
Cancer Lett; 1982; 15(3):261-9. PubMed ID: 6811128
[No Abstract] [Full Text] [Related]
57. Current status of toremifene, a new antiestrogenic agent for the treatment of breast cancer. A symposium. San Antonio, TX, USA, December 7, 1989.
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S1-54. PubMed ID: 1980832
[No Abstract] [Full Text] [Related]
58. [The results of a comparative clinical study of the antiestrogenic preparations toremifene and tamoxifen in locally advanced and disseminated breast cancer].
Konstantinova MM; Gershanovich MA
Vopr Onkol; 1990; 36(10):1182-6. PubMed ID: 2147527
[TBL] [Abstract][Full Text] [Related]
59. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
60. Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer.
Jordan VC; Gottardis MM; Robinson SP; Friedl A
J Steroid Biochem; 1989; 34(1-6):169-76. PubMed ID: 2626014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
